Orchestra BioMed Holdings, Inc. focuses on developing medical devices that address significant unmet needs in cardiovascular care. The company's lead product, Atrioventricular Interval Modulation (AVIM) Therapy, is a bioelectronic treatment designed to lower blood pressure in pacemaker-indicated patients, developed in collaboration with Medtronic. Its second flagship product, the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), is a non-coated drug delivery system co-developed with Terumo Corporation. Rather than commercializing products independently, Orchestra BioMed employs a royalty-based business model, advancing therapies through clinical trials and leveraging its strategic partners for global distribution. The company also develops other bioelectronic therapies, such as CNT-HF for heart failure, and offers ancillary surgical devices. Headquartered in New Hope, Pennsylvania, the company targets multi-billion-dollar global markets through its strategic alliances.
